BRCA2 MUTATION

This early-stage trial tests a combination of two drugs, niraparib and irinotecan, in people with advanced solid tumors that have mutations in DNA repair genes like BRCA, ATM, or PALB2. The main goal is to find a safe dose and understand side effects. About 24 adults with cancers…

This study tests a new drug called ACE-86225106 in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that are hard to treat or no longer respond to standard therapy. The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 298 par…

This study tests whether giving a targeted drug (olaparib) plus hormone therapy for 6 months before prostate removal can eliminate or shrink tumors in men with aggressive prostate cancer. Participants must have specific gene changes (HRR alterations). After surgery, doctors will …

This early-stage trial tests a combination of two oral drugs (olaparib and ASTX727) in adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, PALB2, ATM, or CHEK2). The main goals are to find the safest dose and to see if the drugs can shrink tumors. A…

This early-phase study tests a new treatment for people with metastatic pancreatic or breast cancer that has stopped responding to standard therapies. The treatment combines two chemotherapy drugs with high-dose vitamins and a stem cell transplant to help the body recover. The ma…

This study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About …

This study tests whether adding a new oral drug (elacestrant) to standard olaparib can help people with a specific type of advanced breast cancer (HR+, HER2-, with BRCA1/2 mutations) live longer without the disease getting worse. About 176 participants will receive either the com…

This study tests if a special online group therapy program can help women with BRCA1/2 gene changes who have had breast or ovarian cancer feel less afraid of their cancer returning. About 250 women will either start therapy right away or wait. They will attend weekly online sessi…

This study aims to collect information from 10,000 women in Italy who carry BRCA1 or BRCA2 gene mutations, which increase the risk of certain cancers. By gathering data on where these mutations are found and how they affect health, researchers hope to improve prevention and care …

This study aims to create and test an educational guide about hormone replacement therapy (HRT) for women with BRCA1 or BRCA2 mutations who are planning to have their ovaries and fallopian tubes removed to lower cancer risk. About 50 premenopausal women will use the guide before …

This study tests whether offering online genetic counseling and testing to close relatives of people with BRCA mutations helps more of them get tested compared to usual care. About 820 first-degree relatives (parents, siblings, children) will be randomly assigned to either the on…

This study looks at two new approaches to cancer genetic counseling. The first helps healthcare providers reach out to family members who may have inherited a cancer-related gene change, making it easier for them to get tested. The second uses an online portal to keep patients an…

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer, along with their medical information. The samples will be stored and used by researchers to develop better ways to detect, monitor, and understand cancer over time…